Sahu T, Verma HK, Lvks B. Management of SARS-CoV-2 infection is a major challenge in patients with lymphoid malignancies: Warrants a clear therapeutic strategy. World J Virol 2022; 11(4): 204-207 [PMID: 36159615 DOI: 10.5501/wjv.v11.i4.204]
Corresponding Author of This Article
Henu Kumar Verma, PhD, Research Scientist, Department of Immunopathology, Institute of Lung Health and Immunity, Comprehensive Pneumology Center, Helmholtz Zentrum, Ingolstädter Landstrasse 1, Munich 80331, Bayren, Germany, henu.verma@yahoo.com
Research Domain of This Article
Virology
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Virol. Jul 25, 2022; 11(4): 204-207 Published online Jul 25, 2022. doi: 10.5501/wjv.v11.i4.204
Management of SARS-CoV-2 infection is a major challenge in patients with lymphoid malignancies: Warrants a clear therapeutic strategy
Tarun Sahu, Henu Kumar Verma, Bhaskar Lvks
Tarun Sahu, Physiology, All India Institute of Medical Science, Raipur 492001, Chhattisgarh, India
Henu Kumar Verma, Department of Immunopathology, Institute of Lung Health and Immunity, Comprehensive Pneumology Center, Helmholtz Zentrum, Munich 80331, Bayren, Germany
Bhaskar Lvks, Zoology, Guru Ghasidas Vishwavidyalaya, Bilaspur 495001, Chhattisgarh, India
Author contributions: Sahu T, Verma HK, Lvks B wrote and revised the letter.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Henu Kumar Verma, PhD, Research Scientist, Department of Immunopathology, Institute of Lung Health and Immunity, Comprehensive Pneumology Center, Helmholtz Zentrum, Ingolstädter Landstrasse 1, Munich 80331, Bayren, Germany, henu.verma@yahoo.com
Received: June 5, 2021 Peer-review started: June 5, 2021 First decision: July 27, 2021 Revised: July 28, 2021 Accepted: May 27, 2022 Article in press: May 27, 2022 Published online: July 25, 2022 Processing time: 411 Days and 10.8 Hours
Abstract
Patients with lymphoid malignancies are at a higher risk of coronavirus disease 2019 (COVID-19) infection due to their immunocompromised state and results in higher mortality rates in these patients. Anti-CD 20 therapy is one of the leading causes of immunosuppression that worsens in COVID-19 cases. COVID-19 vaccines, on the other hand, appear to be less beneficial to these patients. App-ropriate treatment and recommendations are required for these COVID-19 patients with lymphoid malignancies.
Core Tip: Patients with hematologic conditions are two times more likely than others to be admitted to the hospital. They are being treated with anti-cancer drugs, which weakens their immune system. As a result, these patients are always at risk of coronavirus disease 2019 (COVID-19). As we know, the COVID-19 is very lethal, and hematological malignancies are likely to increase the risk of negative outcomes from this viral infection. Currently, there are no guidelines for treating COVID-19 infected patients with hematological malignancies.
